CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

55.43 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

37 38 Next >

2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio? ↗

December 17, 2024

Via The Motley Fool

3 Things You Need to Know if You Buy CRISPR Therapeutics Today ↗

December 14, 2024

Via The Motley Fool

2 Biotech Stocks to Buy Hand Over Fist in December ↗

December 07, 2024

Via The Motley Fool

3 of the Best Growth Stocks You Can Buy for Less than $100 ↗

December 05, 2024

Via The Motley Fool

Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More than 65% ↗

November 30, 2024

Via The Motley Fool

Cathie Wood Sees Tesla As 'Largest AI Project On Earth' — Here's Why She's Not Worried About Tech Investments ↗

November 29, 2024

Cathie Wood, founder and CEO of ARK Investment Management LLC, defended the future of artificial intelligence investments while highlighting Tesla Inc. as a cornerstone of technological innovation...

Via Benzinga

Topics Artificial Intelligence

Where Will CRISPR Therapeutics Be in 3 Years? ↗

November 15, 2024

Via The Motley Fool

Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared? ↗

November 26, 2024

Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.

Via Benzinga

Topics Artificial Intelligence

Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts ↗

November 25, 2024

Editas Medicine faces a downgrade to Underperform from BofA, citing competition, limited catalysts, and a reduced price target of $1 from $13.

Via Benzinga

Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip? ↗

November 24, 2024

Via The Motley Fool

3 Monster Stocks in the Making ↗

November 23, 2024

Via The Motley Fool

Deciphering Disruption: Inside Cathie Wood's Latest Plays

November 16, 2024

Cathie Wood's recent stock market activity offers a glimpse into her evolving investment strategy and the potential of disruptive technologies.

Via MarketBeat

Topics Artificial Intelligence ETFs

2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More ↗

November 16, 2024

Via The Motley Fool

3 Unstoppable Growth Stocks I'm Loading $25,000 Each Into by 2029 ↗

November 13, 2024

These three emerging technology leaders are pioneering quantum computing, gene editing, and electric aviation.

Via The Motley Fool

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

November 08, 2024

The rock star fund investor made a lot of big moves on Thursday.

Via The Motley Fool

Smaller Cap Biotechs Are In Season: How Are We Doing? ↗

November 07, 2024

SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range.

Via Talk Markets

3 Companies Building Tomorrow's Game-Changing Technologies ↗

November 05, 2024

These pioneering companies are transforming delivery, medicine, and space access--potentially creating massive opportunities for early investors.

Via The Motley Fool

Thinking of Buying CRISPR Therapeutics Stock? Watch These 2 Key Numbers ↗

November 02, 2024

It won't be able to be profitable without hitting its targets for both of these figures.

Via The Motley Fool

Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500 ↗

October 31, 2024

The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings.

Via Benzinga

Topics ETFs Stocks

12 High-Growth Stocks That Could Deliver Parabolic Returns ↗

October 28, 2024

These 12 innovative companies could deliver exponential returns over the next quarter century.

Via The Motley Fool

The Ultimate Biotech Stock to Buy With $50 Right Now ↗

October 26, 2024

This company might be worth far more than many realize.

Via The Motley Fool

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

October 22, 2024

The aggressive growth icon kicked off the new trading week by buying some of her favorite stocks.

Via The Motley Fool

Why We Buy Stocks ↗

October 21, 2024

Is fear of missing out (FOMO) controlling your portfolio?

Via The Motley Fool

3 Bargain Stocks to Buy in a Market That's Priced for Perfection ↗

October 19, 2024

Yes, bargains can still be found in the stock market.

Via The Motley Fool

Why I Keep Buying These 14 Incredible Growth Stocks ↗

October 16, 2024

This diverse set of growth stocks offers tremendous opportunities in the fields of AI, space, biotech, and emerging industries.

Via The Motley Fool

Topics Artificial Intelligence

Is CRISPR Therapeutics Stock a Buy? ↗

October 13, 2024

The markets this biotech is looking to enter could be extremely lucrative.

Via The Motley Fool

2 Biotech Stocks That Are Screaming Buys This Month ↗

October 12, 2024

They won't remain southbound forever.

Via The Motley Fool

This Healthcare Growth Stock Could Be a Steal of a Deal Right Now ↗

October 05, 2024

CRISPR Therapeutics is trading around multiyear lows.

Via The Motley Fool

These 2 Healthcare Stocks With Big Catalysts on the Horizon Can Make You Richer ↗

October 02, 2024

Market-beating returns could be on the way for patient investors in these two up-and-coming healthcare growth stocks.

Via The Motley Fool

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. ↗

September 26, 2024

Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9

...

37 38 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.